• Big Pharma In Sub-Saharan Africa: Watch Your Step!
  • November 28, 2017
  • Pharmaceutical, medical device, and biotechnology companies, commonly grouped together and referred to as the “Life Sciences Industry,” have the most to risk or lose if they do not approach their dealings in SSA with special care and caution. In the past, the life sciences industry often focused their clinical trials and business transactions in the U.S., Europe, Latin America and Asia. That is no longer the case as SSA has now fully entered the playing field.